Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Japan’s 1st DTP-IPV Vaccine Containing Salk Vaccine to Be Available in December: Daiichi Sankyo
November 26, 2015
- Ex-Exec of Iwaki Subsidiary Embezzled 126 Million Yen
November 25, 2015
- Lilly Files Suit to Bar Launch of Sawai’s Evista Generic
November 24, 2015
- Eisai Gives Global Rights for Selective PDE4 Inhibitor E6005 to US Firm
November 24, 2015
- Kissei to License Endometriosis Treatment to Swiss Bioventure ObsEva
November 24, 2015
- Eisai to Transfer Clinical Diagnostic Business in Japan to Sekisui Chemical for 22.4 Billion Yen
November 24, 2015
- AZ, NCC Link for Non-Clinical Research Utilizing Mass Spectrometry Imaging
November 18, 2015
- Supreme Court Supports Patent Term Extension for Avastin
November 18, 2015
- Boehringer Exec Expects AMED’s Positive Impact on Company
November 18, 2015
- Japan Pharma Market Likely to Reach 9.7 Trillion Yen in 2022: Fuji Keizai
November 18, 2015
- Generic Makers’ Earnings Show Unabated Momentum 1 Year after Medical Fee Reform: Tally
November 17, 2015
- Otsuka Hopes Abilify Maintena Grabs 30% Share in Global Atypical Antipsychotic Market in 2018
November 17, 2015
- AZ Eyes Low Single-Digit Growth over Coming Years in Japan: Pres. Baertschi
November 16, 2015
- Bayer Yakuhin Now Marketing Authorization Holder for Claritin
November 16, 2015
- Taiho Files for Japan Approval of Allergy Drug Bilastine
November 16, 2015
- Senju, Gene Techno to Form Capital Tie-Up for Biosimilar Development in Ophthalmology
November 16, 2015
- NHI Prices of Plavix Generics “Actually 43% Rather than 50% Price of Original Product”: Sawai Pharmaceutical President
November 16, 2015
- Japanese Makers Earn Overseas in 1st Half, Japan Sales Up Only Slightly: Tally
November 13, 2015
- OrphanPacific Aims to Achieve Black Ink in 2017
November 13, 2015
- Astellas to Transfer Global Dermatology Portfolio to LEO Pharma
November 12, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…